Home » Stocks » RNA

Avidity Biosciences, Inc. (RNA)

Stock Price: $20.31 USD -0.44 (-2.12%)
Updated Apr 19, 2021 1:53 PM EDT - Market open
Market Cap 779.88M
Revenue (ttm) 6.79M
Net Income (ttm) -44.36M
Shares Out 37.58M
EPS (ttm) -2.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $20.31
Previous Close $20.75
Change ($) -0.44
Change (%) -2.12%
Day's Open 20.57
Day's Range 19.85 - 21.50
Day's Volume 94,439
52-Week Range 19.12 - 37.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LA JOLLA, Calif., March 25, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...

3 weeks ago - PRNewsWire

LA JOLLA, Calif., March 15, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...

1 month ago - PRNewsWire

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Other stocks mentioned: AVIR, JNJ, LEGN, LLY, NKTX, RHHBY
2 months ago - GuruFocus

LA JOLLA, Calif., Dec. 22, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...

3 months ago - PRNewsWire

LA JOLLA, Calif., Dec. 21, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...

3 months ago - PRNewsWire

The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.

Other stocks mentioned: ABNB, AI, AZEK, DASH, GBIO, PCVX, UCL ...
4 months ago - Seeking Alpha

LA JOLLA, Calif., Nov. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...

5 months ago - PRNewsWire

LA JOLLA, Calif., Sept. 28, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...

6 months ago - PRNewsWire

SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.

7 months ago - PRNewsWire

SAN DIEGO, Aug. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.

8 months ago - PRNewsWire

SAN DIEGO, July 27, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Co...

8 months ago - PRNewsWire

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Other stocks mentioned: BIO, FMTX, IMRA, KROS, PCVX, RPTX, XBI ...
9 months ago - CNN Business

SAN DIEGO, June 16, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Co...

10 months ago - PRNewsWire

Shares of Avidity Biosciences Inc. RNA, +55.66% soared 50% in their trading debut on the Nasdaq on Friday after pricing at the top of their initial public offering range, a sign of heightened interest f...

10 months ago - Market Watch

Avidity Biosciences Inc. RNA, , a biotech the specializes in treatments for muscular disorders, priced its initial public offering at $18 a share late Thursday, the high end of its price range.

10 months ago - Market Watch

SAN DIEGO, June 11, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Con...

10 months ago - PRNewsWire

About RNA

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable... [Read more...]

Industry
Biotechnology
IPO Date
Jun 12, 2020
Stock Exchange
NASDAQ
Ticker Symbol
RNA
Full Company Profile

Financial Performance

In 2020, RNA's revenue was $6.79 million, an increase of 192.67% compared to the previous year's $2.32 million. Losses were -$44.36 million, 79.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price forecast is 44.33, which is an increase of 118.27% from the latest price.

Price Target
$44.33
(118.27% upside)
Analyst Consensus: Strong Buy